Production and Quality Control of Technetium-99m Radiolabeled Monoclonal Antibody

Background and

Binding a monoclonal antibody to tumor associated antigens is an effective method for cancer therapy because these agents can specifically target malignant cells. In fact, monoclonal antibodies are effective agents for diagnosis, grading and treatment of different kinds of cancers. In this research, a new monoclonal antibody against colon cancer cells was prepared and radiolabeling with technetium-99m evaluated.

This research was done in three parts: preparation of hybridoma cell against colon cancer cell line (HT29), production of monoclonal antibody, determination of its characterizations and radiolabeling with technetium-99m.

mAb-D2 is an IgG1 with affinity constant of 7.2 × 109M-1 which can recognize CEA in tumor cells. Radiolabeling showed that 99mTc-HYNIC-mAb-D2 complex is stable, immunoradioactive, and has a desirable biodistribution.

In this study, we gained a new radiopharmaceutical that may be a good candidate for radioimmunoscintigraphy.